Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 533 matching trials from the live ClinicalTrials.gov search.
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Muhammad Furqan
Other
Eligibility
18 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bivalent Norovirus Vaccine Study

NCT01168401
Conditions
Gastroenteritis
Interventions
NoV GI.1/GII.4 Bivalent VLP Vaccine, Saline
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
3
States / cities
Silver Springs, Maryland • St Louis, Missouri • Rochester, New York
Conditions
Small-cell Lung Cancer
Interventions
Proton-beam Therapy for Small Cell Lung Cancer
Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Low Grade Gliomas
Interventions
Proton Radiation Therapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Glioblastoma, Malignant Glioma
Interventions
Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Procedure · Other · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Uveal Melanoma, Metastatic
Interventions
4.7 microCi 225Ac-MTI-201, 9.5 microCi of 225Ac-MTI-201, 19 microCi of 225Ac-MTI-201, 38 microCi of 225Ac-MTI-201, 76 microCi of 225Ac-MTI-201, 152 microCi of 225Ac-MTI-201, 254 microCi of 225Ac-MTI-201, 424 microCi of 225Ac-MTI-201, 564 microCi of 225Ac-MTI-201, 750 microCi of 225Ac-MTI-201, 998 microCi of 225Ac-MTI-201, 1327 microCi of 225Ac-MTI-201
Drug
Lead sponsor
Modulation Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color

NCT01012388
Conditions
Nasolabial Folds
Interventions
Radiesse® Injectable Dermal Filler
Device
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
Los Angeles, California • Chevy Chase, Maryland • Ypsilanti, Michigan + 2 more
Conditions
Prostate Cancer
Interventions
IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Proton (prostate bed) to 70.2 CGE, IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Proton to 66.6 CGE
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2050
U.S. locations
6
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Warrenville, Illinois + 3 more
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, Glioma, Oligoastrocytoma, Oligodendroglioma, WHO Grade 3 Glioma
Interventions
Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Procedure · Radiation · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
34
States / cities
Birmingham, Alabama • Boca Raton, Florida • Miami, Florida + 27 more
Conditions
Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Proton Beam Radiation Therapy, Radiation Therapy, Stereotactic Body Radiation Therapy
Radiation · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Photosensitivity, Microvesicle Particle
Interventions
4% Imipramine Cream, Base Cream
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Fairborn, Ohio
Conditions
Recurrent Head and Neck Carcinoma
Interventions
Intensity-Modulated Radiation Therapy, Proton Radiation, Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Norwalk Vaccine Study

NCT00973284
Conditions
Acute Gastroenteritis, Norwalk Virus Infection
Interventions
Norwalk VLP vaccine, mannitol and sucrose, Norwalk virus
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

Study of the Safety and Immunogenicity of NasoVAX Extension

NCT03760549
Conditions
Influenza
Interventions
Subjects were administered NasoVAX high dose
Drug
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Rockville, Maryland
Completed Phase 2 Interventional Results available

Trial of NanoPac Intratumoral Injection in Lung Cancer

NCT04314895
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer, Lung Cancer, Small Cell, Neoplasm of Lung
Interventions
NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Drug
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Gainesville, Florida • Fort Wayne, Indiana • Baltimore, Maryland + 1 more
Conditions
Cardiovascular Risk Factor, Blood Pressure
Interventions
HEPA Air Filtration, Sham HEPA Air Filtration
Other
Lead sponsor
UConn Health
Other
Eligibility
30 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Conditions
Cardiac Arrhythmia
Interventions
Proton Particle Therapy
Radiation
Lead sponsor
Konstantinos Siontis
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV), Placebo/QHPV
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 12 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
32
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 24 more
Completed Phase 1 Interventional Results available

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

NCT00199849
Conditions
Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Sarcoma
Interventions
NY-ESO-1 Plasmid DNA Cancer Vaccine
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study for GSK1278863A

NCT01319006
Conditions
Anaemia
Interventions
GSK1278863A
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Conditions
Respiratory Syncytial Viruses, Respiratory Tract Infections
Interventions
Ad26.RSV.FA2, Ad35.RSV.FA2, Placebo
Biological · Drug
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Terminated Phase 1Phase 2 Interventional Results available

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

NCT03563157
Conditions
Colorectal Cancer Metastatic, mCRC
Interventions
Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Conditions
Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, PSMA PET Scan, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Glioblastoma Multiforme, Anaplastic Oligoastrocytoma
Interventions
Ad-RTS-hIL-12, veledimex
Biological · Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more